The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib randomized open-label trial of sacituzumab govitecan plus nivolumab or sacituzumab govitecan plus nivolumab and relatlimab as second-line therapy metastatic triple negative breast cancer: SIMONE trial.
 
Adriana Kahn
Consulting or Advisory Role - Pfizer
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Bristol-Myers Squibb (Inst)
 
Jing Du
Research Funding - Novartis (Inst)
 
Sarah Schellhorn
Stock and Other Ownership Interests - Coronado Biosciences; Gilead Sciences; Roche
Honoraria - Cardinal Health
Consulting or Advisory Role - Cardinal Health; Celgene; Eisai; Puma Biotechnology
Research Funding - Genentech; Pfizer
Travel, Accommodations, Expenses - Cardinal Health
 
Michael DiGiovanna
Consulting or Advisory Role - NEC Momentum Acquisitions
Research Funding - Cascadian Therapeutics (Inst); Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - DAKO; NeoMarkers
 
Wajih Kidwai
No Relationships to Disclose
 
Mariya Rozenblit
Consulting or Advisory Role - AstraZeneca; Novartis
 
Daniel O'Neil
No Relationships to Disclose
 
Robert Legare
Consulting or Advisory Role - Unum Therapeutics
 
Nicole Casasanta
Honoraria - IntegrityCE
Travel, Accommodations, Expenses - MD Education; OncLive/MJH Life Sciences
 
Neal Fischbach
Honoraria - Daiichi Sankyo/Lilly; Foundation Medicine
Consulting or Advisory Role - BioTheranostics; Gilead Sciences
Speakers' Bureau - Foundation Medicine
Travel, Accommodations, Expenses - Foundation Medicine
 
Kathleen Fenn
No Relationships to Disclose
 
Kim Blenman
Research Funding - Carevive; SimBioSys
 
Cristina Naranjo Ortiz
No Relationships to Disclose
 
Wei Wei
No Relationships to Disclose
 
Julia Maués
No Relationships to Disclose
 
Ian Krop
Employment - DiaMedica (I); PureTech (I)
Leadership - DiaMedica (I); PureTech (I)
Stock and Other Ownership Interests - DiaMedica (I); PureTech (I)
Honoraria - AstraZeneca; Daiichi Sankyo
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; EMD Serono; Genentech/Roche; Merck; Merck KGaA; Novartis; Seagen
Research Funding - Genentech (Inst); Macrogenics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - anti-murine CD19 monoclonal antibody licensed to PharMingen
 
Eric Winer
Leadership - 4D Path
Consulting or Advisory Role - 4D Path
 
Maryam Lustberg
Honoraria - Novartis
Consulting or Advisory Role - AstraZeneca; Bayer; Gilead Sciences; Lilly; Menarini; Novartis; Osmol Therapeutics; Pfizer
Other Relationship - Cynosure/Hologic
 
Lajos Pusztai
Stock and Other Ownership Interests - Ataraxis
Honoraria - Agendia; AstraZeneca; Bristol-Myers Squibb; Merck @ Co; natera; Radionetics
Consulting or Advisory Role - Agendia; AstraZeneca; Bristol Myers Squibb; Merck; Natera; Personalis; Radionetics
Research Funding - Agendia (Inst); AstraZeneca (Inst); Bristol Myers Squibb (Inst); Exact Sciences (Inst); Menarini (Inst); Merck (Inst); Natera (Inst); Personalis (Inst); Pfizer (Inst)
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences; Foundation Medicine